semaglutide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42575111
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
- 저자
- Lixin Guo, Xiaolei Bao, Kuo-Chin Huang, Kristoffer Jensen Kolnes, Christian Laugesen, Yibing Lu
- 저널
- The lancet. Diabetes & endocrinology
- 공개일
- 2026 Aug 10
- 연구 유형
- 기타
- DOI
- 10.1016/S2213-8587(26)00133-6
문헌 요약
Semaglutide 2·4 mg is a GLP-1 receptor agonist that reduces bodyweight, and provides other cardiometabolic benefits, among people with a BMI at least 30 kg/m 2 or at least 27 kg/m 2 and with weight-related comorbidities. This trial aimed to evaluate the efficacy, tolerability, and safety of semaglutide 2·4 mg in adults from mainland China and Taiwan with…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.